The FDA Have Awarded Orphan Drug Designation to an Experimental Treatment for Dermatomyositis
The US Food and Drug Administration has awarded Orphan Drug Designation to the drug lenabasum as a treatment for dermatomyositis. The use of lenabasum for treating this condition, and others,…